JP2002502589A - ４５個のヒト分泌タンパク質 - Google Patents
４５個のヒト分泌タンパク質Info
- Publication number
- JP2002502589A JP2002502589A JP2000530528A JP2000530528A JP2002502589A JP 2002502589 A JP2002502589 A JP 2002502589A JP 2000530528 A JP2000530528 A JP 2000530528A JP 2000530528 A JP2000530528 A JP 2000530528A JP 2002502589 A JP2002502589 A JP 2002502589A
- Authority
- JP
- Japan
- Prior art keywords
- gene
- seq
- tissues
- polypeptide
- polypeptides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 728
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 272
- 241000282414 Homo sapiens Species 0.000 title abstract description 15
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 21
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 19
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 19
- 239000013598 vector Substances 0.000 claims abstract description 8
- 102000040430 polynucleotide Human genes 0.000 claims description 331
- 108091033319 polynucleotide Proteins 0.000 claims description 331
- 239000002157 polynucleotide Substances 0.000 claims description 330
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 327
- 229920001184 polypeptide Polymers 0.000 claims description 324
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 324
- 230000014509 gene expression Effects 0.000 claims description 202
- 239000000047 product Substances 0.000 claims description 153
- 125000003729 nucleotide group Chemical group 0.000 claims description 137
- 239000002773 nucleotide Substances 0.000 claims description 91
- 238000000034 method Methods 0.000 claims description 56
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 48
- 239000012472 biological sample Substances 0.000 claims description 47
- 239000002299 complementary DNA Substances 0.000 claims description 28
- 150000001413 amino acids Chemical class 0.000 claims description 17
- 238000012217 deletion Methods 0.000 claims description 16
- 230000037430 deletion Effects 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 16
- 239000012634 fragment Substances 0.000 claims description 11
- 230000001575 pathological effect Effects 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 8
- 230000027455 binding Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 230000004071 biological effect Effects 0.000 claims description 5
- 238000004166 bioassay Methods 0.000 claims description 3
- 230000035772 mutation Effects 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims 1
- 108091026890 Coding region Proteins 0.000 abstract description 5
- 238000002405 diagnostic procedure Methods 0.000 abstract description 3
- 238000010188 recombinant method Methods 0.000 abstract description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- 210000001519 tissue Anatomy 0.000 description 604
- 210000004027 cell Anatomy 0.000 description 324
- 235000018102 proteins Nutrition 0.000 description 262
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 249
- 208000035475 disorder Diseases 0.000 description 178
- 206010028980 Neoplasm Diseases 0.000 description 124
- 239000000523 sample Substances 0.000 description 93
- 210000001124 body fluid Anatomy 0.000 description 84
- 239000010839 body fluid Substances 0.000 description 80
- 238000003745 diagnosis Methods 0.000 description 80
- 238000009826 distribution Methods 0.000 description 76
- 201000010099 disease Diseases 0.000 description 71
- 208000026278 immune system disease Diseases 0.000 description 58
- 238000011282 treatment Methods 0.000 description 56
- 239000003153 chemical reaction reagent Substances 0.000 description 51
- 230000004069 differentiation Effects 0.000 description 48
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 45
- 230000001900 immune effect Effects 0.000 description 45
- 210000002381 plasma Anatomy 0.000 description 45
- 210000002966 serum Anatomy 0.000 description 45
- 210000001179 synovial fluid Anatomy 0.000 description 45
- 210000002700 urine Anatomy 0.000 description 45
- 210000002751 lymph Anatomy 0.000 description 44
- 210000000130 stem cell Anatomy 0.000 description 43
- 201000011510 cancer Diseases 0.000 description 41
- 230000001024 immunotherapeutic effect Effects 0.000 description 40
- 206010052428 Wound Diseases 0.000 description 39
- 208000027418 Wounds and injury Diseases 0.000 description 39
- 210000001744 T-lymphocyte Anatomy 0.000 description 36
- 210000004369 blood Anatomy 0.000 description 34
- 239000008280 blood Substances 0.000 description 34
- 208000029462 Immunodeficiency disease Diseases 0.000 description 30
- 238000013519 translation Methods 0.000 description 29
- 208000032839 leukemia Diseases 0.000 description 28
- 230000008569 process Effects 0.000 description 28
- 230000001105 regulatory effect Effects 0.000 description 28
- 230000014616 translation Effects 0.000 description 28
- 206010003246 arthritis Diseases 0.000 description 27
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 27
- 230000004913 activation Effects 0.000 description 26
- 208000030507 AIDS Diseases 0.000 description 25
- 210000004556 brain Anatomy 0.000 description 25
- 230000004083 survival effect Effects 0.000 description 25
- 208000006673 asthma Diseases 0.000 description 24
- 230000001850 reproductive effect Effects 0.000 description 24
- 210000005013 brain tissue Anatomy 0.000 description 23
- 238000009169 immunotherapy Methods 0.000 description 22
- 230000002062 proliferating effect Effects 0.000 description 22
- 230000003542 behavioural effect Effects 0.000 description 21
- 210000000349 chromosome Anatomy 0.000 description 21
- 108010076504 Protein Sorting Signals Proteins 0.000 description 20
- 230000012010 growth Effects 0.000 description 20
- 230000006907 apoptotic process Effects 0.000 description 19
- 210000000987 immune system Anatomy 0.000 description 19
- 208000015122 neurodegenerative disease Diseases 0.000 description 19
- 108020004414 DNA Proteins 0.000 description 18
- 235000001014 amino acid Nutrition 0.000 description 18
- 230000001605 fetal effect Effects 0.000 description 18
- 206010040047 Sepsis Diseases 0.000 description 17
- 230000028993 immune response Effects 0.000 description 17
- 206010039073 rheumatoid arthritis Diseases 0.000 description 17
- 208000012239 Developmental disease Diseases 0.000 description 16
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 16
- 201000004681 Psoriasis Diseases 0.000 description 16
- 229940024606 amino acid Drugs 0.000 description 16
- 230000030741 antigen processing and presentation Effects 0.000 description 16
- 238000001514 detection method Methods 0.000 description 16
- 230000003394 haemopoietic effect Effects 0.000 description 16
- 208000018706 hematopoietic system disease Diseases 0.000 description 16
- 210000002826 placenta Anatomy 0.000 description 16
- 201000000980 schizophrenia Diseases 0.000 description 16
- 208000002874 Acne Vulgaris Diseases 0.000 description 15
- 206010000496 acne Diseases 0.000 description 15
- 210000004185 liver Anatomy 0.000 description 15
- 210000001550 testis Anatomy 0.000 description 15
- 210000004381 amniotic fluid Anatomy 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 14
- 230000002265 prevention Effects 0.000 description 14
- 208000024827 Alzheimer disease Diseases 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 230000024245 cell differentiation Effects 0.000 description 13
- 210000000952 spleen Anatomy 0.000 description 13
- 206010012289 Dementia Diseases 0.000 description 12
- 208000023105 Huntington disease Diseases 0.000 description 12
- 206010033864 Paranoia Diseases 0.000 description 12
- 208000027099 Paranoid disease Diseases 0.000 description 12
- 208000018737 Parkinson disease Diseases 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 230000003169 placental effect Effects 0.000 description 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
- 206010026749 Mania Diseases 0.000 description 11
- 206010061535 Ovarian neoplasm Diseases 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 210000001185 bone marrow Anatomy 0.000 description 11
- 238000011161 development Methods 0.000 description 11
- 230000018109 developmental process Effects 0.000 description 11
- 239000002243 precursor Substances 0.000 description 11
- 230000035755 proliferation Effects 0.000 description 11
- 208000023275 Autoimmune disease Diseases 0.000 description 10
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 10
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 10
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 10
- 206010020751 Hypersensitivity Diseases 0.000 description 10
- 208000024777 Prion disease Diseases 0.000 description 10
- 230000001419 dependent effect Effects 0.000 description 10
- 238000005755 formation reaction Methods 0.000 description 10
- 230000002503 metabolic effect Effects 0.000 description 10
- 230000004770 neurodegeneration Effects 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 9
- 208000012902 Nervous system disease Diseases 0.000 description 9
- 208000025966 Neurological disease Diseases 0.000 description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- 208000008589 Obesity Diseases 0.000 description 9
- 208000024313 Testicular Neoplasms Diseases 0.000 description 9
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 9
- 210000003169 central nervous system Anatomy 0.000 description 9
- 230000013020 embryo development Effects 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 230000001537 neural effect Effects 0.000 description 9
- 235000020824 obesity Nutrition 0.000 description 9
- 108010035532 Collagen Proteins 0.000 description 8
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 8
- 108700026244 Open Reading Frames Proteins 0.000 description 8
- 206010052779 Transplant rejections Diseases 0.000 description 8
- 230000032823 cell division Effects 0.000 description 8
- 230000016396 cytokine production Effects 0.000 description 8
- 230000002124 endocrine Effects 0.000 description 8
- 230000036737 immune function Effects 0.000 description 8
- 230000037451 immune surveillance Effects 0.000 description 8
- 208000027866 inflammatory disease Diseases 0.000 description 8
- 210000001161 mammalian embryo Anatomy 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 210000002741 palatine tonsil Anatomy 0.000 description 8
- 210000005059 placental tissue Anatomy 0.000 description 8
- 230000007261 regionalization Effects 0.000 description 8
- 230000019491 signal transduction Effects 0.000 description 8
- 208000003174 Brain Neoplasms Diseases 0.000 description 7
- 102000008186 Collagen Human genes 0.000 description 7
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 7
- 230000030833 cell death Effects 0.000 description 7
- 229920001436 collagen Polymers 0.000 description 7
- 230000003412 degenerative effect Effects 0.000 description 7
- 210000001723 extracellular space Anatomy 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 208000010544 human prion disease Diseases 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 206010025135 lupus erythematosus Diseases 0.000 description 7
- 201000006417 multiple sclerosis Diseases 0.000 description 7
- 201000008968 osteosarcoma Diseases 0.000 description 7
- 230000024833 regulation of cytokine production Effects 0.000 description 7
- 238000002864 sequence alignment Methods 0.000 description 7
- 201000003120 testicular cancer Diseases 0.000 description 7
- 206010061598 Immunodeficiency Diseases 0.000 description 6
- 208000007466 Male Infertility Diseases 0.000 description 6
- 208000001132 Osteoporosis Diseases 0.000 description 6
- 206010033128 Ovarian cancer Diseases 0.000 description 6
- 206010057644 Testis cancer Diseases 0.000 description 6
- 210000000577 adipose tissue Anatomy 0.000 description 6
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 230000007813 immunodeficiency Effects 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 210000000653 nervous system Anatomy 0.000 description 6
- 210000003463 organelle Anatomy 0.000 description 6
- 210000000963 osteoblast Anatomy 0.000 description 6
- 208000019906 panic disease Diseases 0.000 description 6
- 208000002320 spinal muscular atrophy Diseases 0.000 description 6
- 230000002792 vascular Effects 0.000 description 6
- 206010003805 Autism Diseases 0.000 description 5
- 208000020706 Autistic disease Diseases 0.000 description 5
- 230000004163 JAK-STAT signaling pathway Effects 0.000 description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 5
- 208000028017 Psychotic disease Diseases 0.000 description 5
- 208000000323 Tourette Syndrome Diseases 0.000 description 5
- 208000016620 Tourette disease Diseases 0.000 description 5
- 201000007201 aphasia Diseases 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 230000019771 cognition Effects 0.000 description 5
- 210000002808 connective tissue Anatomy 0.000 description 5
- 210000004443 dendritic cell Anatomy 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 210000003754 fetus Anatomy 0.000 description 5
- 210000005153 frontal cortex Anatomy 0.000 description 5
- 230000001771 impaired effect Effects 0.000 description 5
- 201000003723 learning disability Diseases 0.000 description 5
- 201000001441 melanoma Diseases 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000000926 neurological effect Effects 0.000 description 5
- 230000006576 neuronal survival Effects 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 230000035764 nutrition Effects 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000011164 ossification Effects 0.000 description 5
- 230000002611 ovarian Effects 0.000 description 5
- 201000002528 pancreatic cancer Diseases 0.000 description 5
- 230000008447 perception Effects 0.000 description 5
- 208000020016 psychiatric disease Diseases 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000007958 sleep Effects 0.000 description 5
- 208000019116 sleep disease Diseases 0.000 description 5
- 210000000225 synapse Anatomy 0.000 description 5
- 239000000439 tumor marker Substances 0.000 description 5
- 208000023328 Basedow disease Diseases 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 4
- 208000015023 Graves' disease Diseases 0.000 description 4
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 4
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 4
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 4
- 206010020850 Hyperthyroidism Diseases 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 208000007502 anemia Diseases 0.000 description 4
- 230000033115 angiogenesis Effects 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 210000000941 bile Anatomy 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 238000012937 correction Methods 0.000 description 4
- 210000005257 cortical tissue Anatomy 0.000 description 4
- 230000007368 endocrine function Effects 0.000 description 4
- 210000000750 endocrine system Anatomy 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 230000028023 exocytosis Effects 0.000 description 4
- 201000001881 impotence Diseases 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000003907 kidney function Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000002583 male contraceptive agent Substances 0.000 description 4
- 210000004995 male reproductive system Anatomy 0.000 description 4
- 230000035800 maturation Effects 0.000 description 4
- 210000000066 myeloid cell Anatomy 0.000 description 4
- 210000000440 neutrophil Anatomy 0.000 description 4
- 210000004976 peripheral blood cell Anatomy 0.000 description 4
- 230000001323 posttranslational effect Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 210000002307 prostate Anatomy 0.000 description 4
- 208000017497 prostate disease Diseases 0.000 description 4
- 210000004994 reproductive system Anatomy 0.000 description 4
- 230000002207 retinal effect Effects 0.000 description 4
- 210000004739 secretory vesicle Anatomy 0.000 description 4
- 230000001953 sensory effect Effects 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 210000002027 skeletal muscle Anatomy 0.000 description 4
- 210000002536 stromal cell Anatomy 0.000 description 4
- 230000002992 thymic effect Effects 0.000 description 4
- 230000004218 vascular function Effects 0.000 description 4
- 210000005166 vasculature Anatomy 0.000 description 4
- 208000029483 Acquired immunodeficiency Diseases 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 3
- 241000972773 Aulopiformes Species 0.000 description 3
- 208000005623 Carcinogenesis Diseases 0.000 description 3
- 208000017701 Endocrine disease Diseases 0.000 description 3
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 3
- 208000000527 Germinoma Diseases 0.000 description 3
- 208000021177 Hepatic metabolic disease Diseases 0.000 description 3
- 101001037191 Homo sapiens Hyaluronan synthase 1 Proteins 0.000 description 3
- 102100040203 Hyaluronan synthase 1 Human genes 0.000 description 3
- 208000009164 Islet Cell Adenoma Diseases 0.000 description 3
- 101000931108 Mus musculus DNA (cytosine-5)-methyltransferase 1 Proteins 0.000 description 3
- 208000019547 Placental disease Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 208000000491 Tendinopathy Diseases 0.000 description 3
- 206010043255 Tendonitis Diseases 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000001919 adrenal effect Effects 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 230000037444 atrophy Effects 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 210000002798 bone marrow cell Anatomy 0.000 description 3
- 210000000133 brain stem Anatomy 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 230000036952 cancer formation Effects 0.000 description 3
- 231100000504 carcinogenesis Toxicity 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000036570 collagen biosynthesis Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000004590 computer program Methods 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 230000008482 dysregulation Effects 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 230000002357 endometrial effect Effects 0.000 description 3
- 210000004996 female reproductive system Anatomy 0.000 description 3
- 210000004700 fetal blood Anatomy 0.000 description 3
- 210000002458 fetal heart Anatomy 0.000 description 3
- 230000011132 hemopoiesis Effects 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 230000000626 neurodegenerative effect Effects 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 208000025934 placenta disease Diseases 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 235000019515 salmon Nutrition 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 210000000582 semen Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 210000001258 synovial membrane Anatomy 0.000 description 3
- 201000004415 tendinitis Diseases 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 108010063503 Actinin Proteins 0.000 description 2
- 102000010825 Actinin Human genes 0.000 description 2
- 208000024985 Alport syndrome Diseases 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 102000004321 Atrophin-1 Human genes 0.000 description 2
- 108090000806 Atrophin-1 Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 201000008163 Dentatorubral pallidoluysian atrophy Diseases 0.000 description 2
- 241001269524 Dura Species 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101000597263 Homo sapiens Phosphate-regulating neutral endopeptidase PHEX Proteins 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 101100015375 Mus musculus Gnaz gene Proteins 0.000 description 2
- 206010029098 Neoplasm skin Diseases 0.000 description 2
- 206010031264 Osteonecrosis Diseases 0.000 description 2
- 206010033661 Pancytopenia Diseases 0.000 description 2
- 102100029740 Poliovirus receptor Human genes 0.000 description 2
- 206010038910 Retinitis Diseases 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 2
- 102100028082 Tapasin Human genes 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000002567 autonomic effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 238000010322 bone marrow transplantation Methods 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- 210000003591 cerebellar nuclei Anatomy 0.000 description 2
- 210000001638 cerebellum Anatomy 0.000 description 2
- 208000018631 connective tissue disease Diseases 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 208000037765 diseases and disorders Diseases 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000011124 ex vivo culture Methods 0.000 description 2
- 230000004129 fatty acid metabolism Effects 0.000 description 2
- 201000003115 germ cell cancer Diseases 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 210000000777 hematopoietic system Anatomy 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 208000003215 hereditary nephritis Diseases 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 208000003532 hypothyroidism Diseases 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 201000002364 leukopenia Diseases 0.000 description 2
- 231100001022 leukopenia Toxicity 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 229960004452 methionine Drugs 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000003007 myelin sheath Anatomy 0.000 description 2
- 208000025189 neoplasm of testis Diseases 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 208000004235 neutropenia Diseases 0.000 description 2
- 208000005368 osteomalacia Diseases 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000006320 pegylation Effects 0.000 description 2
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 2
- 108010048507 poliovirus receptor Proteins 0.000 description 2
- 239000013615 primer Substances 0.000 description 2
- 239000002987 primer (paints) Substances 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 208000013363 skeletal muscle disease Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 108010059434 tapasin Proteins 0.000 description 2
- 230000002381 testicular Effects 0.000 description 2
- 206010043554 thrombocytopenia Diseases 0.000 description 2
- 230000006016 thyroid dysfunction Effects 0.000 description 2
- 206010044008 tonsillitis Diseases 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 238000010798 ubiquitination Methods 0.000 description 2
- 230000034512 ubiquitination Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 102000008490 2-Oxoglutarate 5-Dioxygenase Procollagen-Lysine Human genes 0.000 description 1
- 108010020504 2-Oxoglutarate 5-Dioxygenase Procollagen-Lysine Proteins 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 208000020576 Adrenal disease Diseases 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 101100002951 Caenorhabditis elegans asp-17 gene Proteins 0.000 description 1
- 101100228206 Caenorhabditis elegans gly-6 gene Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 241000543381 Cliftonia monophylla Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000006992 Color Vision Defects Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108010077781 F-actin-binding proteins Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 101710160621 Fusion glycoprotein F0 Proteins 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- 206010020675 Hypermetropia Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- LFVLUOAHQIVABZ-UHFFFAOYSA-N Iodofenphos Chemical compound COP(=S)(OC)OC1=CC(Cl)=C(I)C=C1Cl LFVLUOAHQIVABZ-UHFFFAOYSA-N 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 1
- 206010034912 Phobia Diseases 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
- -1 R1881 compound Chemical class 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 102100029937 Smoothelin Human genes 0.000 description 1
- 101710151526 Smoothelin Proteins 0.000 description 1
- 206010058907 Spinal deformity Diseases 0.000 description 1
- 208000037913 T-cell disorder Diseases 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 241000223104 Trypanosoma Species 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 210000002319 adipose dendritic cell Anatomy 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 230000010516 arginylation Effects 0.000 description 1
- 208000017504 atelosteogenesis type II Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000005068 bladder tissue Anatomy 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 230000034127 bone morphogenesis Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000022159 cartilage development Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000017568 chondrodysplasia Diseases 0.000 description 1
- 208000012601 choreatic disease Diseases 0.000 description 1
- 201000004709 chorioretinitis Diseases 0.000 description 1
- 201000007254 color blindness Diseases 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000006251 gamma-carboxylation Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000002873 global sequence alignment Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 150000003278 haem Chemical group 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229960000900 human factor viii Drugs 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- 201000006318 hyperopia Diseases 0.000 description 1
- 230000004305 hyperopia Effects 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 208000017517 male reproductive system disease Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 231100000878 neurological injury Toxicity 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 201000010464 osteogenesis imperfecta type 1 Diseases 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 208000015124 ovarian disease Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000001898 pallidal effect Effects 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000004560 pineal gland Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000012113 pregnancy disease Diseases 0.000 description 1
- 230000001855 preneoplastic effect Effects 0.000 description 1
- 230000013823 prenylation Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000005267 prostate cell Anatomy 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 208000017443 reproductive system disease Diseases 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 230000000698 schizophrenic effect Effects 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000019694 serous adenocarcinoma Diseases 0.000 description 1
- 208000004548 serous cystadenocarcinoma Diseases 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/13—Tumour cells, irrespective of tissue of origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7414198P | 1998-02-09 | 1998-02-09 | |
| US7411898P | 1998-02-09 | 1998-02-09 | |
| US7403798P | 1998-02-09 | 1998-02-09 | |
| US7434198P | 1998-02-09 | 1998-02-09 | |
| US7415798P | 1998-02-09 | 1998-02-09 | |
| US60/074,141 | 1998-02-09 | ||
| US60/074,341 | 1998-02-09 | ||
| US60/074,157 | 1998-02-09 | ||
| US60/074,037 | 1998-02-09 | ||
| US60/074,118 | 1998-02-09 | ||
| PCT/US1999/002293 WO1999040100A1 (en) | 1998-02-09 | 1999-02-04 | 45 human secreted proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002502589A true JP2002502589A (ja) | 2002-01-29 |
| JP2002502589A5 JP2002502589A5 (enExample) | 2006-03-09 |
Family
ID=27535993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000530528A Pending JP2002502589A (ja) | 1998-02-09 | 1999-02-04 | ４５個のヒト分泌タンパク質 |
Country Status (6)
| Country | Link |
|---|---|
| US (8) | US6569992B1 (enExample) |
| EP (1) | EP1053245A4 (enExample) |
| JP (1) | JP2002502589A (enExample) |
| AU (1) | AU2577799A (enExample) |
| CA (1) | CA2320625A1 (enExample) |
| WO (1) | WO1999040100A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7479544B2 (en) | 2002-10-25 | 2009-01-20 | Genentech Inc. | Anti-PRO87299 antibodies |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001034800A1 (en) * | 1999-11-12 | 2001-05-17 | Human Genome Sciences, Inc. | 19 human secreted proteins |
| US20030068623A1 (en) | 1997-06-16 | 2003-04-10 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US8007798B2 (en) | 1997-11-21 | 2011-08-30 | Genentech, Inc. | Treatment of complement-associated disorders |
| US7192589B2 (en) * | 1998-09-16 | 2007-03-20 | Genentech, Inc. | Treatment of inflammatory disorders with STIgMA immunoadhesins |
| US8088386B2 (en) | 1998-03-20 | 2012-01-03 | Genentech, Inc. | Treatment of complement-associated disorders |
| US7419663B2 (en) | 1998-03-20 | 2008-09-02 | Genentech, Inc. | Treatment of complement-associated disorders |
| JP2002502589A (ja) | 1998-02-09 | 2002-01-29 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | ４５個のヒト分泌タンパク質 |
| DE69939227D1 (de) * | 1998-03-20 | 2008-09-11 | Genentech Inc | Menschliches A33-Antigen-ähnliches Protein und dafür kodierende Nukleinsäure |
| WO1999055733A1 (en) * | 1998-04-24 | 1999-11-04 | Smithkline Beecham Corporation | Cloning of a novel 7tm receptor axor-2 |
| US7026448B2 (en) * | 1998-09-01 | 2006-04-11 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| EP1135492A1 (en) * | 1998-11-25 | 2001-09-26 | Millennium Pharmaceuticals, Inc. | 12216 receptor, a g-protein coupled receptor |
| US7026449B2 (en) * | 1999-01-05 | 2006-04-11 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US8410248B2 (en) | 1999-03-12 | 2013-04-02 | Human Genome Sciences Inc. | HWBAO62 polypeptides |
| ATE342979T1 (de) | 1999-08-03 | 2006-11-15 | Millennium Pharm Inc | 15571, ein neues gpcr-ähnliches molekül der secretin-ähnlichen familie und dessen verwendungen |
| JP2003514520A (ja) * | 1999-11-05 | 2003-04-22 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | ２９個のヒト分泌タンパク質 |
| EP1228092A4 (en) * | 1999-11-12 | 2003-11-12 | Human Genome Sciences Inc | 24 HUMAN SECRETED PROTEINS |
| WO2001066744A2 (en) * | 2000-03-06 | 2001-09-13 | Lexicon Genetics Incorporated | Human transporter proteins and polynucleotides encoding the same |
| JP2004528006A (ja) * | 2000-09-29 | 2004-09-16 | インサイト・ゲノミックス・インコーポレイテッド | 分泌タンパク質 |
| WO2002092804A1 (en) * | 2001-05-15 | 2002-11-21 | Biovitrum Ab | Metalloprotease m8 polynucleotides and polypeptides and screening methods |
| AU2003245615A1 (en) * | 2002-06-20 | 2004-01-06 | The Regents Of The University Of California | Compositions and methods for modulating lymphocyte activity |
| US8546541B2 (en) | 2002-06-20 | 2013-10-01 | Washington University | Compositions and methods for modulating lymphocyte activity |
| WO2007001459A2 (en) | 2004-11-15 | 2007-01-04 | Washington University | Compositions and methods for modulating lymphocyte activity |
| US20040248257A1 (en) * | 2003-04-30 | 2004-12-09 | The Scripps Research Institute | SPEX compositions and methods of use |
| US20050186577A1 (en) | 2004-02-20 | 2005-08-25 | Yixin Wang | Breast cancer prognostics |
| KR20180002911A (ko) | 2005-11-04 | 2018-01-08 | 제넨테크, 인크. | 안질환 치료를 위한 보체 경로 억제제의 용도 |
| WO2007120638A2 (en) * | 2006-04-12 | 2007-10-25 | President And Fellows Of Harvard College | Methods and compositions for modulating glycosylation |
| US7776573B2 (en) | 2006-06-01 | 2010-08-17 | Genentech, Inc. | Crystal structure of CRIg and C3b:CRIg complex |
| AU2007313685C1 (en) | 2006-11-02 | 2015-09-17 | Genentech, Inc. | Humanized anti-Factor D antibodies |
| AR066660A1 (es) | 2007-05-23 | 2009-09-02 | Genentech Inc | Prevencion y tratamiento de condiciones del ojo asociadas con su complemento |
| WO2008156676A1 (en) * | 2007-06-15 | 2008-12-24 | President And Fellows Of Harvard College | Methods and compositions for detecting and modulating o-glycosylation |
| CR20170001A (es) | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
| EP2280996B1 (en) | 2008-05-06 | 2016-09-07 | Genentech, Inc. | AFFINITY MATURED CRIg VARIANTS |
| US8957075B2 (en) | 2009-06-01 | 2015-02-17 | President And Fellows Of Harvard College | O-GlcNAc transferase inhibitors and uses thereof |
| US8303952B2 (en) | 2009-06-08 | 2012-11-06 | Washington University | Methods for inducing in vivo tolerance |
| JP2015504413A (ja) | 2011-10-28 | 2015-02-12 | パトリス リミテッド | Ｐａｔ−ｌｍ１エピトープおよびそれを使用するための方法 |
| MX2016001854A (es) | 2013-08-12 | 2016-09-06 | Genentech Inc | Composiciones y metodo para tratar condiciones asociadas con el complemento. |
| EA201692109A1 (ru) | 2014-05-01 | 2017-03-31 | Дженентек, Инк. | Варианты антител к фактору d и их применение |
| TW201713690A (zh) | 2015-08-07 | 2017-04-16 | 再生元醫藥公司 | 抗ａｎｇｐｔｌ８抗體及其用途 |
| WO2017075173A2 (en) | 2015-10-30 | 2017-05-04 | Genentech, Inc. | Anti-factor d antibodies and conjugates |
| JP2018536650A (ja) | 2015-10-30 | 2018-12-13 | ジェネンテック， インコーポレイテッド | 抗ｄ因子抗体変異体コンジュゲート及びその使用 |
| AU2017363143B2 (en) | 2016-11-17 | 2022-07-28 | Regeneron Pharmaceuticals, Inc. | Methods of treating obesity with anti-ANGPTL8 antibodies |
| WO2019126194A1 (en) | 2017-12-18 | 2019-06-27 | Regeneron Pharmaceuticals, Inc. | Angptl8 assay and uses thereof |
| CN112980883B (zh) * | 2021-03-03 | 2022-04-12 | 广州达博生物制品有限公司 | 一种人γ-干扰素病毒载体及其应用 |
| US20220403401A1 (en) * | 2021-06-11 | 2022-12-22 | Monsanto Technology Llc | Methods and compositions for altering protein accumulation |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5001225A (en) * | 1986-12-08 | 1991-03-19 | Georgetown University | Monoclonal antibodies to a pan-malarial antigen |
| US5118617A (en) * | 1989-05-19 | 1992-06-02 | Applied Research Systems Ars Holding N.V. | Saf polypeptide, gene coding therefor, saf promoter and expression methods for expressing foreign dna sequences in streptomyces |
| JP2879303B2 (ja) * | 1993-01-14 | 1999-04-05 | 佑 本庶 | ｃＤＮＡライブラリーの作製方法、および新規なポリペプチドとそれをコードするＤＮＡ |
| US5536637A (en) * | 1993-04-07 | 1996-07-16 | Genetics Institute, Inc. | Method of screening for cDNA encoding novel secreted mammalian proteins in yeast |
| US5744355A (en) * | 1994-10-18 | 1998-04-28 | Mayo Foundation For Medical Education And Research | cDNA cloning and expression of human liver estrogen sulfotransferase |
| US5707829A (en) * | 1995-08-11 | 1998-01-13 | Genetics Institute, Inc. | DNA sequences and secreted proteins encoded thereby |
| US20060223088A1 (en) * | 1997-03-07 | 2006-10-05 | Rosen Craig A | Human secreted proteins |
| JP2001518793A (ja) * | 1997-04-10 | 2001-10-16 | ジェネティックス・インスチチュート・インコーポレーテッド | 分泌発現配列タグ（ｓＥＳＴｓ） |
| US20030073129A1 (en) * | 1998-09-01 | 2003-04-17 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| JP2002502589A (ja) | 1998-02-09 | 2002-01-29 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | ４５個のヒト分泌タンパク質 |
| AU764441B2 (en) | 1998-02-09 | 2003-08-21 | Genset S.A. | cDNAs encoding secreted proteins |
| EP1090118A2 (en) | 1998-06-26 | 2001-04-11 | Incyte Pharmaceuticals, Inc. | Human signal peptide-containing proteins |
| NZ531664A (en) | 1998-09-01 | 2005-07-29 | Genentech Inc | Pro1317 polypeptides and sequences thereof with homology to the semaphorin B glycoprotein family |
| EP1623989B1 (en) | 1999-03-08 | 2007-06-13 | Genentech, Inc. | Compositions and methods for the diagnosis of tumours |
| EP1396543A3 (en) | 1999-07-08 | 2004-03-31 | Research Association for Biotechnology | Primers for synthesizing full length cDNA clones and their use |
| WO2001053312A1 (en) | 1999-12-23 | 2001-07-26 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| EP1274715A2 (en) | 2000-04-06 | 2003-01-15 | Genetics Institute, Inc. | Polynucleotides encoding novel secreted proteins |
| US6812339B1 (en) * | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
| US8067152B2 (en) * | 2006-02-27 | 2011-11-29 | The Fred Hutchinson Cancer Research Center | Liver cancer biomarkers |
-
1999
- 1999-02-04 JP JP2000530528A patent/JP2002502589A/ja active Pending
- 1999-02-04 EP EP99905667A patent/EP1053245A4/en not_active Withdrawn
- 1999-02-04 AU AU25777/99A patent/AU2577799A/en not_active Abandoned
- 1999-02-04 CA CA002320625A patent/CA2320625A1/en not_active Abandoned
- 1999-02-04 WO PCT/US1999/002293 patent/WO1999040100A1/en not_active Ceased
- 1999-08-05 US US09/369,247 patent/US6569992B1/en not_active Expired - Fee Related
-
2002
- 2002-02-05 US US10/062,548 patent/US6924356B2/en not_active Expired - Fee Related
-
2004
- 2004-08-16 US US10/918,446 patent/US20050009085A1/en not_active Abandoned
- 2004-12-03 US US11/002,754 patent/US20060281095A1/en not_active Abandoned
- 2004-12-03 US US11/002,756 patent/US20050153335A1/en not_active Abandoned
- 2004-12-03 US US11/002,755 patent/US20050079537A1/en not_active Abandoned
-
2006
- 2006-12-11 US US11/608,978 patent/US20070154918A1/en not_active Abandoned
-
2008
- 2008-11-20 US US12/274,626 patent/US20090088555A1/en not_active Abandoned
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7479544B2 (en) | 2002-10-25 | 2009-01-20 | Genentech Inc. | Anti-PRO87299 antibodies |
| US7605229B2 (en) | 2002-10-25 | 2009-10-20 | Genentech, Inc. | PRO87299 polypeptides |
| US7863422B2 (en) | 2002-10-25 | 2011-01-04 | Genentech, Inc. | Anti-PRO87299 antibodies |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1053245A4 (en) | 2002-04-17 |
| WO1999040100A1 (en) | 1999-08-12 |
| US20060281095A1 (en) | 2006-12-14 |
| EP1053245A1 (en) | 2000-11-22 |
| US20050009085A1 (en) | 2005-01-13 |
| US20050153335A1 (en) | 2005-07-14 |
| US6569992B1 (en) | 2003-05-27 |
| US20090088555A1 (en) | 2009-04-02 |
| US6924356B2 (en) | 2005-08-02 |
| US20070154918A1 (en) | 2007-07-05 |
| CA2320625A1 (en) | 1999-08-12 |
| US20050079537A1 (en) | 2005-04-14 |
| AU2577799A (en) | 1999-08-23 |
| US20030096982A1 (en) | 2003-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6924356B2 (en) | Human protein HHEPU32 | |
| US20030204071A1 (en) | 109 human secreted proteins | |
| JP2002533058A (ja) | ９７個のヒト分泌タンパク質 | |
| JP2002521055A (ja) | ９８個のヒト分泌タンパク質 | |
| JP2002518010A (ja) | ９４個のヒト分泌タンパク質 | |
| US20070248593A1 (en) | 32 Human Secreted Proteins | |
| US7906634B2 (en) | HEMCM42 nucleic acids | |
| JP2002516103A (ja) | インターロイキン２１およびインターロイキン２２ | |
| JP2002501738A (ja) | ６７個のヒト分泌タンパク質 | |
| JP2009131263A (ja) | ５０個のヒト分泌タンパク質 | |
| JP2002506627A (ja) | ９５個のヒト分泌タンパク質 | |
| US6881823B2 (en) | Human protein HFXJW48 | |
| JP2002500035A (ja) | ３６個のヒト分泌タンパク質 | |
| JP2002520050A (ja) | ７１個のヒト分泌タンパク質 | |
| JP2003525566A (ja) | １２５個のヒト分泌タンパク質 | |
| JP2003524366A (ja) | ６４個のヒト分泌タンパク質 | |
| JP2002505871A (ja) | ３１個のヒト分泌タンパク質 | |
| JP2002514925A (ja) | １９個のヒト分泌タンパク質 | |
| JP2001519179A (ja) | ５３個のヒト分泌タンパク質 | |
| JP2003521865A (ja) | １４８個のヒト分泌タンパク質 | |
| JP2003521216A (ja) | ９０個のヒト分泌タンパク質 | |
| US20010016647A1 (en) | 29 human secreted proteins | |
| JP2003521215A (ja) | ８３個のヒト分泌タンパク質 | |
| US20050069943A1 (en) | 101 human secreted proteins | |
| JP2002504361A (ja) | ３６個のヒト分泌タンパク質 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060113 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060113 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081121 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090220 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090227 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090319 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090327 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090414 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090421 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090710 |